Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

What this Trial Is About

Researchers are evaluating the clinical responsiveness of dermatomyositis using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), a tool established in 2008 to measure disease activity and severity. This ongoing database study at the University of Pennsylvania gathers valuable information on the disease's progression, psychological impact, treatments, and quality of life for patients with dermatomyositis. The study aims to analyze data collected over five years to better understand the clinical course and patient experiences. This observational study collects clinical and patient-reported data including CDASI scores and quality of life assessments related to skin symptoms. The CDASI is a validated outcome measure that helps track how the disease changes over time and how patients respond to treatments. The study does not involve investigational drugs or interventions but rather focuses on monitoring disease activity and patient well-being through surveys and clinical evaluations. Participants will provide informed consent and undergo regular assessments using the CDASI and skin quality of life tools for about one year on average. The study observes changes in disease severity and quality of life to help clinicians evaluate treatment effectiveness and disease management. Data collected contributes to a valuable resource for understanding dermatomyositis and improving patient care over the long term.

Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)